Pranlukast is a Small Molecule owned by Ono Pharmaceutical, and is involved in 1 clinical trial, which was completed.
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
The revenue for Pranlukast is expected to reach a total of $68m through 2029. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pranlukast NPV Report.
Pranlukast is currently owned by Ono Pharmaceutical.
Pranlukast (Onon, Azlaire) is a chromones derivative acts as an anti asthmatic agent. It is formulated as hard gelatin capsules and dry syrup or powder for solution or powder for suspension for oral administration, granule for oral route of administration. It is indicated for the treatment of bronchial asthma and allergic rhinitis.
Ono Pharmaceutical Overview
Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.
Quick View – Pranlukast
|Highest Development Stage|